Sumatriptan in the acute treatment of migraine

Tansey, Michael; Pilgrim, AJ; Lloyd, Kate

doi:10.1016/0022-510x(93)90057-6

Cited by 37 publications

(23 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Second, we assumed that all migraineurs responded identically to each triptan dose, based upon responses in clinical trials 16–21 . Some studies have suggested that nonresponders, those who do not obtain relief after an initial trial of triptans, will consistently fail to respond; while those who do, will consistently respond at higher rates 22–25 . Categorizing individuals as responders and nonresponders would have allowed us to avoid triptan use in nonresponders, effectively decreasing adverse effects without diminishing effectiveness.…”

Section: Commentmentioning

confidence: 99%

When to Stress Over Triptans: A Markov Analysis of Cardiovascular Risk in Migraine Treatment

Orlando¹,

Matchar²

2004

Headache

View full text Add to dashboard Cite

show abstract

Section: Commentmentioning

confidence: 99%

When to Stress Over Triptans: A Markov Analysis of Cardiovascular Risk in Migraine Treatment

Orlando¹,

Matchar²

2004

Headache

View full text Add to dashboard Cite

show abstract

“…While selective 5‐HT 1 receptor agonists like sumatriptan are effective in the acute treatment of migraine (1–3), a number of non‐selective 5‐HT 2 receptor antagonists such as methysergide, pizotifen, cyproheptadine and amitryptiline are used as prophylactic anti‐migraine agents (4). Although efficacious, these compounds lack selectivity and have adverse events which limit their medicinal application (5).…”

Section: Introductionmentioning

confidence: 99%

Neurogenic Dural Protein Extravasation Induced by Meta-Chlorophenylpiperazine (Mcpp) Involves Nitric Oxide and 5-HT_2B Receptor Activation

Johnson¹,

Dl²,

Dieckman³

et al. 2003

Cephalalgia

View full text Add to dashboard Cite

The compound m-chlorophenylpiperazine (mCPP), which is known to trigger migraine-like head pain in some subjects, was evaluated for its ability to induce dural plasma protein extravasation (PPE) in guinea pigs. Intravenous mCPP dose-dependently increased PPE. This effect was inhibited by non-selective 5-HT2 receptor antagonists (methysergide, LY53857, LY215840), by a peripherally restricted 5-HT2 receptor antagonist (xylamidine) and by a 5-HT2B selective receptor antagonist (LY202146). These data suggests that peripheral 5-HT2B receptors mediate mCPP-induced PPE. The nitric oxide synthase inhibitor L-NAME and 5-HT1 agonist sumatriptan also blocked mCPP-induced PPE, suggesting a role for nitric oxide (NO) and the trigeminal system, respectively. NO release has been linked to activation of the 5-HT2B receptor on the vascular endothelium. However, LY202146 did not block PPE induced by electrical stimulation of the trigeminal ganglion. These data are consistent with activation of peripheral 5-HT2B receptors initiating PPE and the theory that selective 5-HT2B antagonists might be effective prophylactic therapies for migraine.

show abstract

“…5‐HT interacts with multiple receptors and numerous studies have emphasized the role of 5‐HT 1 receptors in the acute treatment of migraine headache (for reviews, see Martin, 1997; Schoenen, 1997; Goadsby, 1998). In this respect, the 5‐HT 1 receptor agonist sumatriptan (Peroutka & McCarthy, 1989; Humphrey & Feniuk, 1991; Adham et al ., 1993) has proven to be a highly effective antimigraine compound (Ferrari, 1993; Gross et al ., 1993; Tansey et al ., 1993). Two mechanisms have been proposed to explain its clinical efficacy, namely a vasoconstriction of meningeal blood vessels and an inhibition of the pro‐inflammatory response that results from the release of substance P and calcitonin gene‐related peptide (CGRP) from activated trigeminovascular afferents (Humphrey & Feniuk, 1991; Moskowitz, 1992; Buzzi et al ., 1995).…”

Section: Introductionmentioning

confidence: 99%

No contractile effect for 5‐HT_1D and 5‐HT_1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery

Bouchelet

Case

Olivier

et al. 2000

British J Pharmacology

View full text Add to dashboard Cite

1 Using subtype-selective 5-HT 1 receptor agonists and/or the 5-HT 1 receptor antagonist GR127935, we characterized in vitro the 5-HT receptor that mediates the contraction of human and bovine cerebral arteries. Further, we investigated which sumatriptan-sensitive receptors are present in human coronary artery by reverse-transcriptase polymerase chain reaction (RT ± PCR). 2 Agonists with anity at the 5-HT 1B receptor, such as sumatriptan, alniditan and/or IS-159, elicited dose-dependent contraction in both human and bovine cerebral arteries. They behaved as full agonists at the sumatriptan-sensitive 5-HT 1 receptors in both species. In contrast, PNU-109291 and LY344864, selective agonists at 5-HT 1D and 5-HT 1F receptors, respectively, were devoid of any signi®cant vasocontractile activity in cerebral arteries, or did not aect the sumatriptan-induced vasocontraction. The rank order of agonist potency was similar in both species and could be summarized as 5-HT=alniditan4sumatriptan=IS-159444PNU-109291=LY344864. 3 In bovine cerebral arteries, the 5-HT 1 receptor antagonist GR127935 dose-dependently inhibited the vasoconstrictions elicited by both 5-HT and sumatriptan, with respective pA 2 values of 8.0 and 8.6. 4 RT ± PCR studies in human coronary arteries showed a strong signal for the 5-HT 1B receptor while message for the 5-HT 1F receptor was weak and less frequently detected. Expression of 5-HT 1D receptor mRNA was not detected in any sample.5 The present results demonstrate that the triptan-induced contraction in brain vessels is mediated exclusively by the 5-HT 1B receptor, which is also present in a majority of human coronary arteries. These results suggest that selective 5-HT 1D and 5-HT 1F receptor agonists might represent new antimigraine drugs devoid of cerebro-and cardiovascular eects.

show abstract

Sumatriptan in the acute treatment of migraine

Cited by 37 publications

References 25 publications

When to Stress Over Triptans: A Markov Analysis of Cardiovascular Risk in Migraine Treatment

When to Stress Over Triptans: A Markov Analysis of Cardiovascular Risk in Migraine Treatment

Neurogenic Dural Protein Extravasation Induced by Meta-Chlorophenylpiperazine (Mcpp) Involves Nitric Oxide and 5-HT_2B Receptor Activation

No contractile effect for 5‐HT_1D and 5‐HT_1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery

Contact Info

Product

Resources

About

Sumatriptan in the acute treatment of migraine

Cited by 37 publications

References 25 publications

When to Stress Over Triptans: A Markov Analysis of Cardiovascular Risk in Migraine Treatment

When to Stress Over Triptans: A Markov Analysis of Cardiovascular Risk in Migraine Treatment

Neurogenic Dural Protein Extravasation Induced by Meta-Chlorophenylpiperazine (Mcpp) Involves Nitric Oxide and 5-HT2B Receptor Activation

No contractile effect for 5‐HT1D and 5‐HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery

Contact Info

Product

Resources

About

Neurogenic Dural Protein Extravasation Induced by Meta-Chlorophenylpiperazine (Mcpp) Involves Nitric Oxide and 5-HT_2B Receptor Activation

No contractile effect for 5‐HT_1D and 5‐HT_1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery